Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinchlorimide SCHEMBL28095443 | 0.90 | BRD4 (0.33) | BRD4BRD2 | |
| Succinchlorimide SCHEMBL72 | 0.90 | — | — | |
| Succinchlorimide SCHEMBL1465495 | 0.90 | BRD4 (0.30) | BRD4BRD2 | |
| Succinchlorimide SCHEMBL5897812 | 0.90 | — | — | |
| Succinchlorimide SCHEMBL3032531 | 0.87 | — | — | |
| Succinchlorimide SCHEMBL31009667 | 0.87 | — | — | |
| Succinchlorimide SCHEMBL30695169 | 0.87 | — | — | |
| Succinchlorimide SCHEMBL10703237 | 0.87 | — | — | |
| Succinchlorimide SCHEMBL18424832 | 0.87 | — | — | |
| Succinchlorimide SCHEMBL27913334 | 0.86 | FFAR3 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249301-B | Elution solution and preparation method of radionuclide astatine-211 for targeting nuclide drug | 砹尔法纽克莱(宁波)医疗科技有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-114249301-B | Elution solution and preparation method of radionuclide astatine-211 for targeting nuclide drug | 砹尔法纽克莱(宁波)医疗科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-114249301-A | Elution solution and preparation method of radionuclide astatine-211 for targeted nuclide drug | 砹尔法纽克莱(宁波)医疗科技有限公司 | 2022-03-29 | — | — | CN | disclosed |
| EP-2844657-B1 | THERAPEUTIC COMPOUNDS | CHANGZHOU LE SUN PHARMACEUTICALS LTD (CN) | 2017-04-12 | — | — | EP | disclosed |
| US-9062039-B2 | Therapeutic compounds | CHANGZHOU LE SUN PHARMACEUTICALS LIMITED (CN) | 2015-06-23 | — | — | US | disclosed |
| US-20150105413-A1 | THERAPEUTIC COMPOUNDS | CHANGZHOU LE SUN PHARMACEUTICALS LIMITED (CN) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105413-A1 | THERAPEUTIC COMPOUNDS | CDK9, CDK19, CDK2 | BRD4 133/4885BRD2 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.